Skip to Main Content

Pathogenesis of the cardiometabolic risk in youth with type 1 diabetes

  • Study HIC#:2000025170
  • Last Updated:07/15/2021

Brief Summary:

The purpose of this study is to quantitate hepatic de novo lipogenesis (DNL) in youth with poorly-controlled type 1 diabetes (T1D) (HbA1c >8.5%), youth with T1D who achieve targeted glycemic control (HbA1c <7.5%) and lean controls. Hypothesis: Youth with poor glycemic control experience higher fractional hepatic DNL during the fasting and the postprandial states than youth who achieve targeted glycemic control and lean controls.

  • Age13 years - 22 years
  • GenderBoth
  • Start Date11/20/2019
  • End Date03/31/2021

Trial Purpose and Description

The study will explore the role of hepatic de novo lipogenesis in hypertriglyceridemia in type 1 diabetes 

Eligibility Criteria

Inclusion Criteria:

  • 13-22 years old
  • HbA1c >8.5% for the group with poorly controlled diabetes
  • HbA1c <7.5% for the well-controlled patients
  • T1D for at least 12 months (T1D groups only)
  • Negative pregnancy test (all groups)

Exclusion Criteria:

  • Baseline creatinine >1
  • Being on medications affecting glucose concentrations other than insulin
  • Positive pregnancy test
  • Endocrinopathies
  1. Yes (lean, no T1D)

Principal Investigator

For more information about this study, contact:

Or contact the Help us Discover team on: